Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Oral Care in connection with the acquisition of Dutch dental care provider De Tandartsengroep (DTG)
Mandate

Vinge advises Oral Care in connection with the acquisition of Dutch dental care provider De Tandartsengroep (DTG)

February 19, 2025 Banking and Finance Employment and Benefits M&A Intellectual Property Commercial Agreements

DTG operates 31 clinics and 8 dental laboratories in the Netherlands. Oral Care is a portfolio company of Axcel VI and operates a network of dental clinics in Sweden, Norway and the Netherlands. To support this expansion, Axcel VII is joining Axcel VI as a shareholder in Oral Care.

The transaction is subject to customary approval by the Dutch Health Care Authority and the Dutch Authority for Consumers and Markets (ACM).

Vinge's team consisted of Christina Kokko, Manon de Cooman, Gustav Wahlberg, Helena Liljenberg, Josef Groow (M&A), Alice Göransson (Employment Law), Avid Axelryd (Intellectual Property), Calle Tengwall Pagels, August Ahlin, Sara Jansson (Banking and Finance), Carla Håkansson, Katja Hägglund (Commercial Agreements), Frida Lansfjord, Jacob Guve, Alma Rotsman, Augus Olding (Assistants).

Read the client's press release here.

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

 Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026